STOCKS TELEGRAPH

Tag: EVFM

  • Evofem Biosciences, Inc. (EVFM) Stock Rallying Premarket. Any Reasons?

    Evofem Biosciences, Inc. (EVFM) stock was up by 6.56% at $0.3950 premarket, at the last check on Tuesday. In the previous session, the stock lost 2.37% at the closing price of $0.3707 on December 20.

    Currently, the 163.14 million outstanding shares of the company trade at a market capitalization of $61.95 million.

    What is going on?

    While the EVFM stock was in the red in the previous session, it is trading in the green in today’s premarket session. There is no official news from the company but some other background noises are ringing in the market. As per reports, Saundra L Pelletier (CEO EVFM) and Justin J. File (CFO EVFM) bought shares of the company on Monday. Moreover, Mr. File bought 40,594 shares of the stock at a price of $0.37 per share. Hence, the total worth of the transaction was $15,019.78. Furthermore, Pelletier purchased 135,000 shares of the company at a price of $038 per share, with a total value of $51,300.

    In addition, news of great revenue estimates for the current fiscal quarter is also circulating in the market. According to Wall Street brokerages, EVFM is expected to post sales of $2.76 million for the current quarter.

    EVFM’s Collaboration with Orion Biotechnology

    On December 16, both the companies disclosed their collaboration for developing MPT product candidates. According to the agreement, the compatibility of Orion’s OB-002 will be tested in EVFM’s Phexxi®. Moreover, its goal would be the development of a Multipurpose Prevention Technology (MPT) product candidate. Furthermore, the MPT will include indications like the prevention of HIV in women.

    Orion’s OB-002

    OB-002 is Orion’s novel CCR5 antagonist, which has shown best-in-class in vitro potency in trials. In a non-human primate model, OB-002 demonstrated 100% effectiveness in blocking HIV transmission. Moreover, it also showed positive results in a Phase 1 study.

    EVFM’s Phexxi®

    Launched in September 2020, Phexxi is EVFM’s prescription contraceptive gel. Currently, the company is expecting top-line data from its Phase 3 trial in the second half of 2022. The trial will demonstrate Phexxi’s effectiveness in the prevention of chlamydia and gonorrhea.

    EVFM’s Financial Highlights

    On November 16, the company announced the financial results of its third quarter of 2021.

    In the third quarter of 2021, EVFM incurred a net loss of $74.1 million or $0.48 per share.

    Furthermore, the company ended the quarter with cash, cash equivalents of $14.9 million.

  • Why Evofem Biosciences, Inc. (EVFM) stock is falling today?

    Evofem Biosciences, Inc. (EVFM) announced the public offering of its common stock after which the EVFM stock price saw a downtrend of 21.03% today to drop at $1.84 as of this writing. EVFM stock was down by 9.34% at the previous closing. So what you need to know now?

    Public Offering of EVFM Common Stock

    Evofem Biosciences, Inc. (EVFM) is a biopharmaceutical company mainly focused on women’s sexual and reproductive health through the development and commercializing of its various products. EVFM stock recently announced the offering of  17,142,857 shares of its common stock at $1.75 per share public price. Underwriters are granted a 30-day option to buy up to additional 2,571,428 shares worth $4.5 million of Evofem common stock at the public offering price less than the underwriting discounts and commissions. $30 million gross proceeds are estimated for this offering without deducting the underwriting discounts, commissions, and other related expenses. The offering will end on March 29, 2021.

    EVFM is planning to use the net proceeds resulted from this offering in various areas including the commercialization of Phexxi (lactic acid, citric acid, and potassium bitartrate) a contraceptive vaginal gel for the prevention of pregnancy, in the united states of America. Furthermore, these net proceeds will support the advertising activities across television as well as streaming and digital channels of Evofem. Some part of these net proceeds will help in the continuation of phase 3 clinical analysis of EVOGUARD and its related activities in which EVFM is observing the EVO100 for the prevention of infections that transmit sexually.

    “Get Phexxi”: A Marketing campaign

    Evofem started the “Get Phexxi” campaign on Valentine’s day via television, streaming, and digital channels that achieved significant results according to the EVFM officials. The campaign resulted an increase of 73% in ex-factory sales of Phexxi in February 2021 and these sales of the first quarter of 2021 exceeded the full-year sales level of 2020 by March 12. Evofem stock distributed 2,400 Phexxi units in February 2021 which is 30% higher than the prior month.

    Conclusion

    The penny EVFM stock price is continuing the downtrend in the stock market today following the public offering of shares of its common stock and no one knows how long this bearish sentiment will continue. Though EVFM got significant results in its marketing campaign of Phexxi still more development is required for future growth.

  • 24 stocks trending in pre-market

    ‎Ocugen Inc. (OCGN) stock soared 77.6% to $1.43 in the pre-market trading after ‎signing a binding letter of intent (LOI) with Bharat Biotech to develop Bharat Biotech’s COVID-19 ‎vaccine candidate, COVAXIN, for the United States market.‎

    ‎Sundial Growers Inc. (NASDAQ: SNDL) shares are trading up 1.25% at $0.486 at the ‎time of writing after announcing completion of financial restructuring and debt-free status. Company’s ‎‎52-week ranged between $0.14 to $3.88. COVID-19 Pandemic – The government presents its daily ‎update.‎

    ‎Jaguar Health Inc. (JAGX), a Biotechnology company, rose about 55.89% at $0.617 in ‎pre-market trading Wednesday after releasing voting results from special meeting of stockholders & ‎December 23rd investor webinar.‎

    ‎FuelCell Energy Inc. (FCEL) stock moved up 8.42 percent to $11.65 in the pre-market ‎trading.‎

    ‎Onconova Therapeutics Inc. (ONTX) gained over 32.93% at $0.57 in pre-market ‎trading Wednesday December 23, 2020 following the announcement of FDA permission for study to ‎proceed under its investigational new drug application for multi-kinase CDK4/6 Inhibitor ON 123300.‎

    ‎Castor Maritime Inc. (CTRM) is up more than 2.39% at $0.1585 in pre-‎market ‎hours ‎Wednesday December 23, 2020. The stock had dropped over -2.33% to $0.15 in the ‎last ‎trading ‎session.‎

    ‎Riot Blockchain Inc. (RIOT) is down more than -4.4% at $14.0 in pre-market hours ‎Wednesday December 23, 2020 after reporting an expected 65% increase in bitcoin mining hash rate ‎capacity resulting from the purchase and future deployment of 15,000 S19 Pro and S19j Pro Antminers ‎from Bitmain Technologies Limited .The stock had jumped over 32.65% to $14.65 in the last trading ‎session.‎

    Before the trading started on December 23, 2020, Ideanomics Inc. (IDEX) is up ‎‎4.21% to reach $2.23. It has been trading in a 52-week range of $0.28 to $4.75.‎

    ‎Aurora Mobile Limited (JG) tumbled over -1.46% at $4.72 in pre-market trading ‎today after reporting that it has entered into a partnership agreement a global leading new energy ‎vehicle manufacturer to deliver an enhanced intelligent driving experience.‎

    ‎Velodyne Lidar Inc. (VLDR) is up more than 6.21% at $29.08 in pre-market hours ‎Wednesday December 23, 2020 after revealed the joining of the Qualcomm smart cities accelerator ‎program. The stock had jumped over 10.94% to $27.38 in the last trading session.‎

    ‎Magnite Inc. (NASDAQ: MGNI) shares are trading up 17.21% at $31.81 ‎at ‎the ‎time ‎of ‎writing. Company’s 52-week ranged between $4.09 to $26.63. Analysts have ‎a ‎consensus ‎price ‎target ‎of $30.‎

    ‎Sorrento Therapeutics Inc. (SRNE) grew over 10.66% at $7.99 in pre-market trading ‎today after declaring that it has submitted an emergency use authorization application to the FDA for ‎COVI-STIX™ rapid test for the detection of SARS-CoV-2 Viral Antigen.‎

    ‎UP Fintech Holding Limited (TIGR), a Capital Markets company, dropped about -‎‎2.79% at $7.66 in pre-market trading Wednesday.‎

    ‎Energous Corporation (WATT) stock moved up 13.98 percent to $2.12 in the pre-‎market trading following the declaration from the company that current board director Dan Fairfax has ‎been named chairman of the board as current Chairman Robert J.‎

    ‎Acasti Pharma Inc. (ACST) stock soared 25.92% to $0.3148 in the pre-‎‎‎‎market ‎trading. ‎The most recent rating by Oppenheimer, on September 01, 2020, is a Perform.‎

    ‎Tonix Pharmaceuticals Holding Corp. (TNXP) gained over 5.15% at $0.6008 in pre-‎market trading Wednesday December 23, 2020 after revealing an agreement whereby Tonix has ‎acquired the exclusive license to the University of Geneva’s technology for using oxytocin to treat ‎insulin resistance and related syndromes, including obesity, from privately held Katana ‎Pharmaceuticals, Inc.‎

    ‎BP p.l.c. (BP) is up more than 2.34% at $20.96 in pre-market hours Wednesday ‎December 23, 2020. The stock had dropped over -0.97% to $20.48 in the last trading session.‎

    Before the trading started on December 23, 2020, Evofem Biosciences Inc. (EVFM) ‎is up 6.61% to reach $2.58 after reporting that it will participate in Medicaid National Drug rebate ‎program for Phexxi® Effective January 1, 2021. It has been trading in a 52-week range of $1.91 to $7.21.‎

    ‎Cloudera Inc. (CLDR) is up more than 5.6% at $15.46 in pre-‎‎‎‎‎market ‎hours ‎Wednesday December 23, 2020. The stock had jumped over 13.31% ‎to ‎‎$14.64 ‎in ‎the ‎last ‎trading ‎session.‎

    ‎Advaxis Inc. (ADXS) stock soared 39.07% to $0.4357 in the pre-market trading ‎following the announcement of listing transfer to Nasdaq Capital Market and additional 180-day ‎eExtension by Nasdaq to regain compliance with minimum bid price rule.‎ The most recent rating by ‎Barclays, on August 03, 2016, is an Overweight. ‎

    ‎Nikola Corporation (NASDAQ: NKLA) shares are trading down -2.97% at $16.33 at ‎the time of writing after reporting that Nikola and Republic Services (NYSE: RSG) have discontinued ‎their collaboration on refuse truck development. Company’s 52-week ranged between $10.30 to ‎‎$93.99. Analysts have a consensus price target of $20.‎

    Before the trading started on December 23, ‎‎2020, ‎‎Oragenics ‎Inc. ‎‎(OGEN) ‎is ‎up ‎‎8.3% ‎to reach $0.4841. It has been trading in a 52-‎week ‎range of $0.36 to ‎‎$2.09.‎

    ‎Bionano Genomics Inc. (BNGO) grew over 1.45% at $0.56 in pre-market trading ‎today after reporting publication revealing in side-by-side comparison that method using PacBio ‎sequencing detects only 72% of the large structural variants detected by Optical Genome Mapping ‎with Saphyr.‎

    ‎Palatin Technologies Inc. (PTN) gained over 7.96% at $0.61 in pre-‎‎‎‎‎‎‎market ‎trading ‎Wednesday December 23, 2020.‎

  • 20 Trending Stocks In Biotechnology Industry That Need Your Attention

    20 Trending Stocks In Biotechnology Industry That Need Your Attention

    Biotechnology is considered to be the backbone of many industrial sectors and it makes a significant contribution to the well being of society. Every single day we saw changes in every sector as we experience advancements of knowledge and the new technological breakthroughs.  One of the industries that constantly change is the biotechnology industry.

    2020 is the year of continuous development and improvement in drug research. This industry is the leading rapidly growing sector of the economy. There are various trends in the biotechnology industry that the world should expect in the coming years such as the production of personalized medicines thanks to the advancement in genetics and continuous development and improvement in drug research.

    Let’s take a quick look at the 20 leading companies which are following new trends in the biotechnology sector:

    Vaxart Inc. (NASDAQ: VXRT)

    Vaxart Inc. (NASDAQ: VXRT) shares were trading up 46.79% at $7.78 at the time of writing on Monday. Vaxart Inc. (NASDAQ: VXRT) share price went from a low point around $0.25 to briefly over $17.49 in the past 52 weeks, though shares have since pulled back to $7.78. VXRT market cap has remained high, hitting $766.25M at the time of writing, giving it a price-to-sales ratio of more than 90.

    Vaxart Inc. has revealed that the U.S. Food and Drug Administration (FDA) has completed its review of the Investigational New Drug (IND) application for its Phase 1 clinical trial evaluating its oral COVID-19 vaccine candidate. Vaxart Inc. also gave an update on its COVID-19 program.

    Cassava Sciences Inc. (NASDAQ: SAVA)

    Cassava Sciences Inc. (NASDAQ: SAVA) last closed at $7.75, in a 52-week range of $1.05 to $10.95. Cassava Sciences has announced the final results of a Phase 2bclinical study of Sumifilam in patients with Alzheimer’s Disease. Sumifilam is the first of a new class of drug compounds that bind to a protein called Filamin A. Cassava Sciences Inc. (SAVA) has earlier held a conference call on September 14.  Cassava Sciences Inc.’s market cap has remained high, hitting $182.51 million at the time of writing.

    Immunomedics Inc. (IMMU)

    Immunomedics Inc. (IMMU) stock soar by 97.99% to $83.65. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Gilead Sciences Inc. (NASDAQ: GILD) has earlier announced that it has decided to buy biotech company Immunomedics Inc for $21 billion. This decision will strengthen its cancer portfolio by gaining access to a promising drug.  Immunomedics Inc. (IMMU) has a total market capitalization of $19.19 billion.

    Sorrento Therapeutics Inc. (NASDAQ: SRNE)

    Sorrento Therapeutics Inc. (NASDAQ: SRNE) shares headed rising, higher as much as 17.88%. The most recent rating by H.C. Wainwright, on July 31, 2020, is at a Buy. Sorrento Therapeutics Inc. (NASDAQ: SRNE) has earlier disclosed that it has signed an exclusive license agreement with Mayo Clinic for an antibody-drug-nanoparticle albumin-bound (nab) immune complexes (ADNICs) platform targeting many types of human diseases including various solid and liquid tumors. Sorrento Therapeutics Inc. has a market cap of $1.86 billion.

    Novan Inc. (NASDAQ: NOVN)

    Novan Inc. (NASDAQ: NOVN) rose 13.00% after gaining more than $0.06 on Monday. Novan Provides Pipeline and Priority Development Programs Update. Novan Inc. (NOVN) gave a pipeline and priority development programs update. Novan Inc.’s share price went from a low point around $0.22 to briefly over $3.72 in the past 52 weeks, though shares have since pulled back to $0.53. Novan Inc.’s market cap has remained high, hitting $82.02 million at the time of writing.

    Inovio Pharmaceuticals Inc. (NASDAQ: INO)

    Inovio Pharmaceuticals Inc. (NASDAQ: INO) stock soar by 12.30% to $11.32. The most recent rating by ROTH Capital, on July 01, 2020, is at a Sell. Inovio Pharmaceuticals Inc. (INO) has earlier signed a manufacturing agreement with Thermo Fisher Scientific. Thermo Fisher Scientific has signed a letter of intent to manufacture INOVIO’s DNA COVID-19 vaccine candidate INO-4800.

    Evofem Biosciences Inc. (NASDAQ: EVFM)

    Evofem Biosciences Inc. (NASDAQ: EVFM) Shares headed rising, higher as much as 11.90% after Evofem Biosciences to present data at the 2020 STD prevention Virtual Conference from Phase 2b Trial of EVO100 for prevention of Chlamydia and Gonorrhea in Women. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    iBio Inc. (AMEX: IBIO)

    iBio Inc. (AMEX: IBIO) rose 9.28% after gaining more than $0.18 on Monday. iBio Inc. (AMEX: IBIO) has earlier disclosed that it has selected IBIO-201, its LicKM-ubunit vaccine, as its leading candidate for the prevention of SARS-CoV-2 infection. iBio revealed earlier the preclinical immunization studies with IBIO-200 and IBIO-201, combined with select adjuvants from the Infectious Disease Research Institute, induced anti-SARS-CoV-2 antibodies.  iBio Inc has a market capitalization of $379.31 million.

    Clovis Oncology Inc. (CLVS)

    Clovis Oncology Inc. (CLVS) last closed at $7.00, in a 52-week range of $2.93 to $17.37. CLVS has traded up 138.91% from its 52-weeks low and traded down -59.70% from its 52-weeks high. Analysts have a consensus price target of $9.00. Clovis Oncology Inc. (CLVS) has earlier announced Oral Plenary Session Presentation at the International Gynecologic Cancer Society (IGCS)digital annual global meeting.

    Heat Biologics Inc. (NASDAQ: HTBX)

    Heat Biologics Inc. (NASDAQ: HTBX) stock soar by 1.82% to $1.12. The most recent rating by ROTH Capital, on June 20, 2016, is at a Buy. Heat Biologics Inc. (HTBX) has earlier participated in a virtual panel, entitled, “New Approaches to COVID-19: Hidden Breakthroughs,” being held on Thursday, September 10. Heat Biologics has also issued a key patent on combination platform therapy. Heat Biologics Inc. has a total market capitalization of $170.96 million.

    VBI Vaccines Inc. (NASDAQ: VBIV)

    VBI Vaccines Inc. (NASDAQ: VBIV) shares headed rising, higher as much as 12.82% after VBI Vaccines to present additional biomarker data from VBI-1901 Phase 1/2a Study in Recurrent GBM in an E-Poster at ESMO Virtual Congress 2020. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy. Its market capitalization has remained high, hitting $813.82 million.

    Dynavax Technologies Corporation (NASDAQ: DVAX)

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 13.37% after gaining more than $0.67 on Monday. Valneva and Dynavax have announced a Commercial supply agreement for Inactivated, adjuvanted COVID-19 vaccine. This is a commercial partnership for the supply of Dynavax’s CpG 1018 adjuvant for use in Valneva’s SARS-CoV-2 vaccine candidate, VLA2001. Dynavax will supply CpG 1018 to produce up to 100 million doses of vaccine in 2021. Valneva has the opportunity to purchase up to an additional 90 million doses through 2025.

    Zosano Pharma Corporation (NASDAQ: ZSAN)

    Zosano Pharma Corporation (NASDAQ: ZSAN) last closed at $1.72, in a 52-week range of $0.41 to $2.45. Zosano Pharma Corporation (ZSAN) is scheduled to participate in a Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020. At the conference, Zosano Pharma Corporation will present the company overview. Zosano Pharma Corporation has a total market capitalization of $138.86 million at the time of writing.

    Moderna Inc. (NASDAQ: MRNA)

    Moderna Inc. (NASDAQ: MRNA) stock soar by 7.30% to $63.67. The most recent rating by SVB Leerink, on September 08, 2020, is at an Underperform. Moderna Inc. (MRNA) has earlier named Michael Millette as Managing Director, Canada effective immediately. Michael Millette has joined Moderna Inc in August 2020 as Vice President. Moderna Inc has a total market cap of $24.37 billion at the time of writing.

    9 Meters Biopharma Inc. (NASDAQ: NMTR)

    9 Meters Biopharma Inc. (NASDAQ: NMTR) Shares headed rising, higher as much as 12.61%. 9 Meters Biopharma Inc. (NASDAQ: NMTR) is scheduled to participate in the upcoming two conferences in September including H.C. Wainwright: 22nd Annual Global Investment Conference and Oppenheimer Fall Healthcare Life Sciences & MedTech Summit. These two conferences are scheduled to take place on September 15 and September 23, respectively.

    Ampio Pharmaceuticals Inc. (AMEX: AMPE)

    Ampio Pharmaceuticals Inc. (AMEX: AMPE) rose 10.80% after gaining more than $0.08 on Monday. Ampio Pharmaceuticals Inc. (AMPE) has revealed positive results in the early trial for intravenous Ampion treatment for COVID-19 patients on September 9, 2020. The Phase I trial was continued in the supervision of Michael Roshon, MD, Ph.D., Chief of Staff at Penrose-St. Francis Hospital in Colorado Springs, Colorado.

    Novavax Inc. (NASDAQ: NVAX)

    Novavax Inc. (NASDAQ: NVAX) last closed at $105.80, in a 52-week range of $3.54 to $189.40. Novavax Inc. (NVAX) is scheduled to participate in the upcoming three conferences including Cantor Virtual Global Healthcare Conference, Morgan Stanley Virtual 18th Annual Global Healthcare Conference, and Leerink CyberRx Series: Vaccine Forum on September 15, 16, and 23, respectively. It has earlier participated in Citi 15th Annual BioPharma Virtual Conference, and H.C. Wainwright 22nd Annual Global Investment Conference on September 10, and 14, 2020, respectively.

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS)

    Marinus Pharmaceuticals Inc. (NASDAQ: MRNS) stock soar by 5.50% to $2.11. The most recent rating by H.C. Wainwright, on July 01, 2020, is at a Buy. Marinus Pharmaceuticals Inc. (MRNS)has disclosed that it has entered into a five-year development contract with the Biomedical Advanced Research and Development Authority (BARDA) to support the development of IV ganaxolone for the treatment of refractory status epilepticus (RSE).

    Onconova Therapeutics Inc. (NASDAQ: ONTX)

    Onconova Therapeutics Inc. (NASDAQ: ONTX) Shares headed falling, lower as much as -3.28%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy. Onconova Therapeutics Inc. (NASDAQ: ONTX) has earlier participated in two virtual events including Marcus Evans Healthcare Investment Webinar on September 10 and H.C. Wainwright 22nd Annual Global Investment Conference onSeptmerb 14. It is scheduled to participate in the 2nd Annual RAS-Targeted Drug Development Conference on September 16, 2020.

    Trevena Inc. (NASDAQ: TRVN)

    Trevena Inc. (NASDAQ: TRVN) last closed at $2.08, in a 52-week range of $0.46 to $3.68. In the past 52-weeks of trading, Trevena Inc. (TRVN) stock fluctuated between the low of $0.46 and a high of $3.68. It has moved up $352.17% from its 52-weeks low and moved down -43.48% from its 52-weeks high. Its market capitalization is $306.38 million at the time of writing.